Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036347 | 1.00 | KDM4E (0.54) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6385399 | 0.85 | KDM4E (0.60) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| SCHEMBL1027115 | 0.84 | KDM4E (0.62) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| SCHEMBL10339724 | 0.78 | KDM4E (0.56) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| SCHEMBL11500783 | 0.74 | KDM4E (0.51) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| SCHEMBL5762073 | 0.71 | MAOB (0.53) | KDM4EMAOBPSMB8PSMB5 | |
| SCHEMBL31369827 | 0.71 | CA2 (0.54) | KDM4EMAOBPSMB8PSMB5TP53 | |
| SCHEMBL28205795 | 0.71 | ALOX15 (0.50) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| SCHEMBL21836463 | 0.70 | MAOB (0.51) | KDM4EMAOBALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18331257 | 0.69 | MAOB (0.54) | KDM4EMAOBALOX15MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615906-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092154-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040198750-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-07 | — | — | US | claimed |
| US-7547794-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1615906-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092154-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040198750-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198750-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, MAP3K6, PACSIN2 | KDM4E 2358/4885MAOB 3049/4885ALOX15 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.